Hybrid Assistive Limb Application in Multiple Sclerosis Patients
Effect of Hybrid Assistive Limb (HAL) Application on Locomotor Function and Balance Parameters in Multiple Sclerosis Patients
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Hybrid Assistive Limb (HAL)
What it measured
Main measures
10-Meter Walk Test (10mWT)
Baseline (study start) and at 2 months.
Walking and mobilityTimed Up and Go Test (TUG)
Baseline (study start) and at 2 months.
Walking and mobility6-Minute Walk Test (6MWT)
Baseline (study start) and at 2 months.
Walking and mobilityBalance performance assessed using the TecnoBody D-Wall system
Baseline (study start) and at 2 months.
Walking and mobilityStride Length Assessed by TecnoBody Walker View
Baseline and at 2 months
Walking and mobilityWalking Speed Assessed by TecnoBody Walker View
Baseline and at 2 months
Walking and mobilityDouble Support Time Assessed by TecnoBody Walker View
Baseline and at 2 months
Walking and mobilityGait Symmetry Index Assessed by TecnoBody Walker View
Baseline and at 2 months
Walking and mobility
Other measures (1)
Disease severity assessed by the Expanded Disability Status Scale (EDSS)
Baseline (study start) and at 2 months.
Disability progression
Who could take part
MS (type not specified) · 18 to 50
Show the full criteria
Inclusion criteria
* No previous robotic rehabilitation. * Completion of the 10-meter walk test. * Mini mental status score ≥24. * MASS score \<2. * EDSS \<6.
Exclusion criteria
* History of serious degenerative disease. * Presence of open wounds. * History of thoracic surgery. * Chronic respiratory diseases. * Presence of unstable cardiovascular disease. * Medical conditions that prevent mobilization.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The Hybrid Assistive Limb (HAL) exoskeleton detects bioelectrical signals from the muscles, responds to the intention of voluntary movement, and provides biological feedback. In this study, the effects of HAL application on walking performance and balance in patients with multiple sclerosis will be examined in a single-center, controlled design. Participants will undergo walking rehabilitation with HAL for 1 hour per day, 5 days a week, for a total of 2 months. Walking and balance performance will be assessed before and after the intervention using the 10-Minute Walk Test (10MWT) to measure maximum walking speed, the 6-Minute Walk Test (6MWT) to evaluate walking endurance and cardiorespiratory performance, and the Timed Up and Go Test (TUG) to assess functional mobility and dynamic balance. Additionally, walking parameters and static balance will be measured using Tecnobody systems. Appropriate statistical tests will be applied, and a significance level of p\<0.05 will be considered.
Loading reviews and guidelines…
History
Started
Oct 2025
Main results due
Dec 2025
Finished
Feb 2026